TMPRSS11D and acute myeloid leukemia: Among them, 52.6% (10/19) were associated with intermediate prognostic risks and 47.4% (9/19) with poor prognostic risks (Figure 3A), as assessed by patients’ age, cytogenetics and gene mutations.38 In contrast, among the 86 AML patients who were HAT‐L4 negative in their bone marrow cells posttreatment (Table S1), 25.6% (22/86) were associated with better prognostic risks, 69.8% (60/86) with intermediate prognostic risks, and 4.6% (4/86) with poor prognostic risks (Figure 3A), indicating that posttreatment HAL‐4 expression in bone marrow cells was associated with poor prognosis.